Search published articles


Showing 4 results for هاشم دباغیان
Review of Antidiabetic Plants in Iranian Traditional Medicine and their Efficacy
F Hashem Dabaghian , M Kamalinejad , A Shojaii , M Abdollahi Fard , S.a Ghushegir ,
year 11, Issue 41 (supplement 8 2012)
Abstract

High prevalence of diabetes mellitus and its complications and increasing use of complementary therapies, especially herbal therapies, and the need of developing countries to use their indigenous medical methods, motivated us to introduce some plants used in Iranian traditional medicine for The treatment of this disease. The topic of “ziabetes”(the synonym of diabetes) in some of Iranian traditional medical texts were studied and herbal therapies of this disease were collected. Some edible plant compounds introduced and scientific names of plants in these compounds were identified. Pubmed and Scopus databases were searched for studies regarding hypoglycemic effects of these medicinal herbs on animal or human subjects. Many medicinal herbs &minerals in single or compound form have been used in Iranian traditional medicine. Plants such as Punica granatum, Rosa damascene, Plantago psyllium, Glycyrrhiza glabra, Coriandrum sativum, Portulaca oleracea and Rumex patientia are the most popular ones. Recent studies on animal or human subjects have shown the hypoglycemic effects of some of these plants. Reassessment of the effects of some antidiabetic plants used in Iranian traditional medicine, proved their efficacy mainly in animals. However, we need more clinical trials to prove safety &efficacy of these herbs and compounds.


Effects of Rosa canina L. Fruit on Glycemia and Lipid Profile in Type 2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
F Hashem Dabaghian, M Abdollahifard, F Khalighi Sigarudi, M Taghavi Shirazi, A Shojaee, Z Sabet, H Fallah Huseini,
year 14, Issue 55 (9-2015)
Abstract

Background: Rosa canina L. (rose hip) has been traditionally used to treat diabetes mellitus in Iran. However, no scientific human study has determined its efficacy in diabetic patients.

Objective: This study was conducted to evaluate the efficacy and safety of R. canina fruit aqueous extract in type 2 diabetic patients.

Methods: Sixty patients with type 2 diabetes, aged 35 - 60 years with fasting blood glucose levels between 130 to 200 mg/dL and HbA1c between 7 - 9% despite using conventional oral hypoglycemic drugs were divided randomly to two groups. Two groups of 25 and 23 patients completing the trial received 750 mg R. canina fruit extract and 750 mg toast powder as placebo two times a day respectively for three months.

Fasting blood glucose (FBG) and glycosylated hemoglobin (HbA1c) as primary outcomes and postprandial blood glucose (PBG), lipid profile and hepatic and renal function tests as secondary outcomes were determined at baseline and at endpoint of treatment. The patients were asked to note down any gastrointestinal or other side effects during the study.

Results: The FBG level decreased significantly (P = 0.002) in R. canina group after 3 months compared to the baseline. In addition total cholesterol/HDL-C was significantly (P = 0.02) decreased in the R. canina group compared to the baseline. Other blood parameters were not significantly changed during the study compared with placebo and baseline. No serious side effects were reported in both groups during the study.

Conclusion: Rosa canina 3-month administration to type 2 diabetic patients may reduce fasting blood glucose and total cholesterol/HDL-C without any side effect.


Effects of topical Persian medicine Amygdalus communis L. var. Amara kernel oil on the symptoms of knee osteoarthritis: a randomized, triple-blind, active, and placebo-controlled clinical trial
Saeed Kianbakht, Farzaneh Nabati, Fataneh Hashem Dabaghian,
year 22, Issue 87 (12-2023)
Abstract
Background: The Amygdalus communis L. var. Amara (bitter almond) kernel oil (ACKO) is used topically for palliation of musculoskeletal and joint pains in the Traditional Persian Medicine. Also, it had anti-inflammatory effects in experimental studies. Objective: Evaluation of the efficacy and safety of ACKO in the symptomatic treatment of knee osteoarthritis. Methods: One hundred and fifty six patients were equally randomized to apply ACKO, diclofenac, or placebo to their knees every 8 hours for 1 month. Fifty two, 50, and 51 patients in the ACKO, diclofenac, and placebo groups, respectively, finished the trial. At the trial’s start and end, the symptoms were assessed using the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) questionnaire. Also, hematological, and liver and kidney function tests were performed. Results: Both ACKO and diclofenac reduced the symptoms significantly more than the placebo (P ˂ 0.001). The percent changes of the WOMAC pain and stiffness scores in the ACKO group were similar to the diclofenac group while the percent changes of the WOMAC function and total scores in the ACKO group were less than the diclofenac group (P ˂ 0.001). ACKO and diclofenac had no significant effect on the blood tests. Moreover, no adverse effect was identified. Conclusions: Topical ACKO and diclofenac are safe, and superior to placebo in reducing the symptoms of OA. While ACKO is similar to diclofenac in alleviating pain and stiffness, ACKO is less effective than diclofenac in improving the WOMAC total and function scores.

The effect of a standardized polyherbal formulation for endometriosis-associated pain: A randomized double-blind placebo-controlled clinical trial
Elham Akhtari, Fataneh Hashem-Dabaghian, Amirhossein Jamshidi, Akram Fallah, Majid Dadmehr,
year 23, Issue 91 (8-2024)
Abstract
Background: Dysmenorrhea, dyspareunia and endometriosis-associated pain are considered the main complications in young women with endometriosis. Proscur capsule contains several traditional herbal medicines that have shown anti-inflammatory, antioxidant, anti-androgenic, anti-estrogenic, pelvic pain reducing and analgesic effects in previous pre-clinical and clinical studies. Objective: This study aimed to investigate the clinical efficacy and safety of a standardized polyherbal formulation (proscur) for endometriosis-associated pain in young women with endometriosis. Methods: This study was a single-center, randomized, double-blinded, placebo-controlled, clinical trial. A total of 90 patients aged 20–45 years with endometriosis-associated pain were enrolled. Participants were randomly assigned to the proscur or placebo groups in a ratio of 1:1 and efficacy evaluation was conducted at day 30, 60 and 90. The participants orally administered proscur or placebo two times a day for 12 weeks. The study outcomes were measured based on a change of visual analogue scale (VAS) score and the short form endometriosis health profile questionnaire (EHP-5). Results: We observed an increase in pain relief in women who receive proscur. The serum measures of CA-125 declined in those who received proscur. Intervention was well tolerated, and no serious adverse events occurred. Conclusions: Our study showed that proscur relieved endometriosis-associated pain and CA-125 level with minimal side-effects after treatment. Therefore, proscur combined with standard medical therapy could provide more clinical benefits for patients with endometriosis-associated pain.

Page 1 from 1     

© 2025 CC BY-NC 4.0 | Journal of Medicinal Plants

Designed & Developed by : Yektaweb